Korsana
- Employees
- 11–50
- Business Model
- B2B
- Website
- korsana.com
- Total Funding
- $175.0M
- Last Round
- $150.0M Series AFeb 2026
- Rounds
- 2
About
Biopharmaceutical company developing novel therapies targeting amyloid-beta plaques for Alzheimer's disease and other neurodegenerative conditions.
Summary
Korsana is a Biotech company. It has raised $175.0M in total across 2 rounds, most recently a $150.0M Series A round in Feb 2026. Investors include Wellington Management, Fairmount and TCG Crossover.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company